The Incidence, Inheritance, and Prognostic Significance of Polymorphisms in the RASSF1A Gene in Children With Wilms Tumors
Genetic Data
+ genetic Data
+ genetic Data
Collected from today forward - ProspectiveUrogenital Diseases+14
+ Female Urogenital Diseases and Pregnancy Complications
+ Kidney Diseases
Case-Control
Comparing exposures between individuals with and without disease in order to identify potential risk factors.Summary
Study start date: August 1, 2004
Actual date on which the first participant was enrolled.OBJECTIVES: Primary Determine the presence of the A133S polymorphism in the RASSF1A tumor suppressor gene by screening germline DNAs of children with Wilms' tumor. Determine the inheritance pattern of the A133S polymorphism by evaluating the parents of children who carry this polymorphism. Secondary Determine the differences in age at diagnosis, stage, histology, site of primary tumor, and outcome, between patients with vs without the A133S polymorphism. Determine whether the S131F RASSF1A variant is a true polymorphism in these patients. Determine the polymorphic differences in this gene between these patients based on ethnicity and sex. OUTLINE: This is a multicenter study. Patients are stratified according to age at diagnosis, stage, histology, site of primary tumor, and outcome. Genomic DNA samples are purified from peripheral blood of patients and controls and analyzed by polymerase chain reaction for the RASSF1A gene. DNA is also analyzed from parents of patients with the A133S polymorphism. PROJECTED ACCRUAL: A total of 471 participants (229 Wilms' tumor patients and 200 control participants plus 42 parents) will be accrued for this study.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.471 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Case-Control
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Until 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
DISEASE CHARACTERISTICS: Diagnosis of Wilms' tumor OR Control participants matched for race, sex, and age No prior or concurrent history of cancer OR Parents of children involved in the study PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 232 locations
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, United StatesOpen University of Alabama at Birmingham Comprehensive Cancer Center in Google MapsUniversity of South Alabama Cancer Research Institute
Mobile, United StatesPhoenix Children's Hospital
Phoenix, United StatesArizona Cancer Center at University of Arizona Health Sciences Center
Tucson, United States